Analytical Data
-
Gene name
KDM6B
- Application
-
Alternative Names
(JmjC domain-containing protein 3)(Jumonji domain-containing protein 3)(Lysine demethylase 6B)([histone H3]-trimethyl-L-lysine(27) demethylase 6B)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15054
-
Expression Region
1176-1505aa
-
Molecular Weight
41.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KDM6B, also known as Jumonji Domain Containing 6B, is a histone demethylase that plays a crucial role in the regulation of gene expression through the removal of methyl groups from lysine 27 on histone H3 (H3K27me3). This modification is a key epigenetic marker associated with gene silencing and is involved in various biological processes including stem cell differentiation, development, and the maintenance of pluripotency. Dysregulation of KDM6B has been implicated in several diseases, particularly cancer, where altered gene expression patterns can lead to tumorigenesis and metastasis. Therefore, the study of KDM6B and its recombinant protein holds significant promise for understanding the mechanistic pathways of epigenetic regulation. Researchers have focused on developing recombinant KDM6B proteins to investigate their enzymatic activity, molecular interactions, and potential as therapeutic targets. Furthermore, understanding how KDM6B functions in the context of histone modifications can provide insights into the epigenetic landscape of various diseases, paving the way for new strategies in epigenetic therapy. As a result, KDM6B is a focal point of research aimed at elucidating its role in epigenetics and its potential as a biomarker or therapeutic target in oncology and regenerative medicine.
